Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso

Yanagihara, Gabriela Rezende; Paiva, Aline Goulart de; Neto, Maurílio Pacheco; Torres, Larissa Helena; Shimano, Antonio Carlos; Louzada, Mário Jefferson Quirino; Annoni, Raquel; Penoni, Álvaro César de Oliveira

doi:10.1016/j.rbo.2014.05.012

Cited by 22 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 Outros estudos associam o uso crônico de omeprazol com a má absorção do cálcio pelos ossos, podendo levar à osteoporose, e consequente aumento de fraturas ósseas. 13 Estudos recentes também indicam que o consumo exagerado dos IBPs está diretamente ligado à deficiência do ferro e magnésio, minerais fundamentais ao metabolismo humano, que estão relacionados ao aumento da susceptibilidade à pneumonia e infecções entéricas. 1,8,14 Introdución: Los inhibidores de la bomba de protones (IBP) son una de las clases terapéuticas más recetados en el mundo, y omeprazol es el representante frente a las listas de medicamentos esenciales.…”

Section: E Da Organizaçãounclassified

Perfil de usuários com prescrição de omeprazol em uma Unidade Básica de Saúde do Sul do Brasil: considerações sobre seu uso racional

Hipólito

Rocha

Oliveira³

2016

Rev Bras Med Fam Comunidade

View full text Add to dashboard Cite

Introdução: Os inibidores da bomba de prótons (IBPs) são uma das classes terapêuticas mais prescritas no mundo, sendo omeprazol o representante nas listas de medicamentos essenciais. Estudos indicam que o uso a curto prazo dos IBPs pode ser seguro, apesar de estar relacionado efeitos adversos a longo prazo. Objetivo: Avaliar o perfil dos usuários com prescrição de omeprazol em uma Unidade Básica de Saúde (UBS), relacionando com tempo de uso, dose e indicação. Métodos: Estudo transversal no qual foram avaliados os prontuários de usuários com prescrições de omeprazol atendidas no mês de maio de 2014 pela farmácia de uma UBS. Resultados: Foram incluídos no estudo 349 pacientes, sendo 75,4% do sexo feminino. A média de medicamentos prescritos por pacientes foi de 4,5 e a idade média de 64,6 anos. A dose de 20mg foi encontrada em 69,8% dos usuários, 84,3% tem prescrição mais de seis meses, e a doença do refluxo e a úlcera gástrica foram as indicações mais citadas; 29,5% dos pacientes não tinham registro de motivo de uso do omeprazol. Conclusão: O maior tempo de uso do omeprazol está associado com maior idade e número de medicamentos prescritos, podendo estes fatores estarem relacionados com o uso irracional de omeprazol, por vezes sem justificativa em prontuário e com tempo prolongado de uso.

show abstract

Section: E Da Organizaçãounclassified

Perfil de usuários com prescrição de omeprazol em uma Unidade Básica de Saúde do Sul do Brasil: considerações sobre seu uso racional

Hipólito

Rocha

Oliveira³

2016

Rev Bras Med Fam Comunidade

View full text Add to dashboard Cite

show abstract

“…Omeprazole (OME) is used for the treatment of gastrointestinal disorders such as dyspepsia, peptic ulcer, gastroesophageal reflux or Helicobacter pylori infection (Kosma et al, 2016;Seoane et al, 2017). It is a proton pump inhibitor (PPI) (Yanagihara et al, 2015), that acts through irreversible blocking of the terminal phase of gastric acid secretion in the gut by inhibiting the H + /K + ATPase proton pump in parietal cells. This in turn decreases the amount of acid in the stomach (Paroni Sterbini et al, 2016;Seoane et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Toxicogenetic study of omeprazole and the modulatory effects of retinol palmitate and ascorbic acid on Allium cepa

et al. 2018

View full text Add to dashboard Cite

Omeprazole (OME) is a proton pump inhibitor used for the treatment of various gastric and intestinal disease; however, studies on its effects on the genetic materials are still restricted. The present study aimed to evaluate possible toxicogenic effects of OME in Allium cepa meristems with the application of cytogenetic biomarkers for DNA damage, mutagenic, toxic and cytotoxic effects. Additionally, retinol palmitate (RP) and ascorbic acid (AA) were also co-treated with OME to evaluate possible modulatory effects of OME-induced cytogenetic damages. OME was tested at 10, 20 and 40 μg/mL, while RP and AA at 55 μg/mL and 352.2 μg/mL, respectively. Copper sulphate (0.6 μg/mL) and dechlorinated water were used as positive control and negative control, respectively. The results suggest that OME induced genotoxicity and mutagenicity in A. cepa at all tested concentrations. It was noted that cotreatment of OME with the antioxidant vitamins RP and/or AA significantly (p < 0.05) inhibited and/or modulated all toxicogenic damages induced by OME. These observations demonstrate their antigenotoxic, antimutagenic, antitoxic and anticitotoxic effects in A. cepa. This study indicates that application of antioxidants may be useful tools to overcome OME-induced toxic effects.

show abstract

“…Further investigation is recommended in future studies, considering a more representative sample, in order to identify other factors that may be interfering with the risk of osteoporosis and that have not reached the proposed level of significance or have not been studied in this work. The relationship between the use of antisecretory (proton pump inhibitors) and bone metabolism has been pointed out in the literature by some researchers [19,20], although it is not yet well elucidated. It is supposed that this fact is explained by the elevation of the gastric hydrogen ion potential (pH), which would affect the absorption of calcium, since the mineral is insoluble in basic medium.…”

Section: Discussionmentioning

confidence: 99%

“…It is supposed that this fact is explained by the elevation of the gastric hydrogen ion potential (pH), which would affect the absorption of calcium, since the mineral is insoluble in basic medium. An experimental study in which 50 rats were submitted to prolonged use of omeprazole, in different dosages, observed bone demineralization of the femur of animals exposed to high doses of omeprazole, which may suggest susceptibility to bone fractures [19].…”

Section: Discussionmentioning

confidence: 99%

Analysis of risk factors for osteopenia and osteoporosis among adults and elderly in primary health care

Sgarbi¹,

Lopes²,

Alvarenga³

2020

Int J Innov Educ Res

View full text Add to dashboard Cite

Objective: To analyze the distribution of risk factors for osteopenia and osteoporosis among adults and elderly in primary care. Method: sectional study of quantitative approach. Random sample extracted from registered adults and elderly from the five Family Health Strategy units belonging to an Expanded Family Health and Primary Care Center in Dourados, MS. Data collected between March and December 2015. The sample consisted of 44 adults and 103 elderly, of which only 109 performed all examinations. Body mass index, bone densitometry, serum calcium, 25 serum hydroxyvitamin D and a structured questionnaire were used. Results: The factors that were significantly associated with the risk of osteopenia and osteoporosis (p <0,05) were female gender, alcohol consumption and normal body mass index. Conclusion: the identification of these risk factors made it possible to trace their distribution profile, which will be of great value for carrying out health promotion actions and prevention of these diseases in Primary Health Care.

show abstract

Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso

Cited by 22 publications

References 20 publications

Perfil de usuários com prescrição de omeprazol em uma Unidade Básica de Saúde do Sul do Brasil: considerações sobre seu uso racional

Perfil de usuários com prescrição de omeprazol em uma Unidade Básica de Saúde do Sul do Brasil: considerações sobre seu uso racional

Toxicogenetic study of omeprazole and the modulatory effects of retinol palmitate and ascorbic acid on Allium cepa

Analysis of risk factors for osteopenia and osteoporosis among adults and elderly in primary health care

Contact Info

Product

Resources

About